Surrozen reported second quarter 2026 results with $5.0 million in collaboration revenue from Boehringer Ingelheim and a net income of $50.2 million, driven by non-cash gains on warrant and tranche liabilities. The company announced plans to submit an IND application for its lead candidate SZN-8141 by the end of Q3 2026 and initiate the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026, with initial data expected in H2 2027. Additionally, the U.S. PTAB denied Merck’s post-grant review petition challenging Surrozen’s patent No. 12,297,278. Surrozen operates as a biotechnology company developing Wnt-based therapeutics for sight-threatening ophthalmic conditions.